• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CORRECTION -- International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 04, 2025

    10/31/25 8:35:00 AM ET
    $BLTE
    $COE
    $HCM
    $LOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Other Consumer Services
    Real Estate
    Get the next $BLTE alert in real time by email

    NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- In a release issued yesterday October 30, 2025 by Virtual Investor Conferences, please note several agenda items were modified. The corrected release follows:

    Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Tuesday, November 04, 2025, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the U.S.

    Representatives from participating companies based in Australia, China, Hong Kong, Germany, Spain, Sweden, and the Cayman Islands will respond to questions during formal presentations. The conference is targeted to all categories of investors and analysts interested in international companies.

    There is no fee for participants to log in, attend live presentations and/or ask questions.

    Pre-registration is suggested. Please register here: www.adr.db.com/dbvic

    November 04th Agenda (US Eastern Standard Time):

    • 8:00 AM: HUTCHMED (China) Limited (AIM: HCM, NASDAQ:HCM, and HKEX:13)
    • 8:30 AM: First Pacific Company Ltd ((HKEX: 142, OTC:FPAFY)
    • 9:00 AM: Viomi Technology Co., Ltd (NASDAQ:VIOT)
    • 9:30 AM:  Epiroc AB ((Nasdaq Stockholm: EPIA, OTC:EPOAY)
    • 10:00 AM: Yiren Digital Ltd. (NYSE:YRD)
    • 10:30 AM: Belite Bio, Inc  (NASDAQ:BLTE)
    • 11:00 AM: Deutsche Lufthansa AG ((FRA: LHA, OTCQX:DLAKY)
    • 11:30 AM:  Lotus Technology Inc (NASDAQ:LOT)
    • 12:00 PM: 51Talk Online Education Group (NYSE:COE)
    • 12:30 PM: Radiopharm Theranostics Ltd (NASDAQ:RADX, ASX: RAD))
    • 13:00 PM: Repsol S.A ((BME: REP, OTCQX:REPYY)

    The presentations will be available for replay after the Conference.

    In addition to specializing in administering cross-border equity structures such as American and Global Depositary Receipts, Deutsche Bank provides corporates, financial institutions, hedge funds and supranational agencies around the world with trustee, agency, escrow and related services. The Bank offers a broad range of services for diverse products, from complex securitizations and project finance to syndicated loans, debt exchanges and restructurings.

    For further information, please contact:

    Meredith Zaritheny

    Deutsche Bank AG

    Press & Media Relations

    Tel. +19297424613



    Email [email protected]

    Deutsche Bank provides commercial and investment banking, retail banking, transaction banking and asset and wealth management products and services to corporations, governments, institutional investors, small and medium-sized businesses, and private individuals. Deutsche Bank is Germany's leading bank, with a strong position in Europe and a significant presence in the Americas and Asia Pacific.

    Deutsche Bank is sponsoring the Deutsche Bank Depositary Receipt Investor Conference solely for informational purposes. Deutsche Bank does not prepare, review, approve or edit any presentations, statements, documents or other information or materials, whether in written, electronic or verbal form, provided by any company participating in such conference, and disclaims any responsibility for the accuracy or adequacy of any such information or materials. Deutsche Bank is not promoting, endorsing or recommending any company participating in the conference.

    The Depositary Receipts have been registered pursuant to the US Securities Act of 1933 (the "Act"). The investment or investment service which is the subject of this notice is not available to retail clients as defined by the UK Financial Conduct Authority. This notice has been approved and/or communicated by Deutsche Bank AG New York. The services described in this notice are provided by Deutsche Bank Trust Company Americas (Deutsche Bank) or by its subsidiaries and/or affiliates in accordance with appropriate local registration and regulation. Deutsche Bank is providing the attached notice strictly for information purposes and makes no claims or statement, nor does it warrant or in any way represent, as to the accuracy or completeness of the details contained herein or therein. This announcement appears as a matter of record only. Neither this announcement nor the information contained herein constitutes an offer or solicitation by Deutsche Bank or any other issuer or entity for the purchase or sale of any securities nor does it constitute a solicitation to any person in any jurisdiction where solicitation would be unlawful. No part of this notice may be copied or reproduced in any way without the prior written consent of Deutsche Bank. Past results are not an indication of future performance. Copyright© November 2025 Deutsche Bank AG. All rights reserved.



    Primary Logo

    Get the next $BLTE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLTE
    $COE
    $HCM
    $LOT

    CompanyDatePrice TargetRatingAnalyst
    Belite Bio Inc
    $BLTE
    1/26/2026$195.00Buy
    BofA Securities
    Belite Bio Inc
    $BLTE
    1/6/2026$191.00Overweight
    Morgan Stanley
    Belite Bio Inc
    $BLTE
    12/2/2025$194.00Neutral → Outperform
    Mizuho
    Belite Bio Inc
    $BLTE
    11/24/2025$154.00Overweight
    Cantor Fitzgerald
    Belite Bio Inc
    $BLTE
    11/20/2025$105.00Neutral
    Mizuho
    HUTCHMED (China) Limited
    $HCM
    9/22/2025$13.75Equal-Weight → Underweight
    Morgan Stanley
    HUTCHMED (China) Limited
    $HCM
    5/13/2025Buy → Hold
    HSBC Securities
    Radiopharm Theranostics Limited
    $RADX
    3/12/2025$15.00Buy
    B. Riley Securities
    More analyst ratings

    $BLTE
    $COE
    $HCM
    $LOT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities initiated coverage on Belite Bio with a new price target

    BofA Securities initiated coverage of Belite Bio with a rating of Buy and set a new price target of $195.00

    1/26/26 10:01:23 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on Belite Bio with a new price target

    Morgan Stanley initiated coverage of Belite Bio with a rating of Overweight and set a new price target of $191.00

    1/6/26 8:54:10 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Belite Bio upgraded by Mizuho with a new price target

    Mizuho upgraded Belite Bio from Neutral to Outperform and set a new price target of $194.00

    12/2/25 8:17:09 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    $COE
    $HCM
    $LOT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO)

    SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in the upcoming Asia-Pacific Academy of Ophthalmology (APAO) 2026 Congress, taking place February 5-7, 2026 in Hong Kong. The presentations will include previously disclosed topline results from the Phase 3 DRAGON study of tinlarebant in adolescents with Stargardt disease type 1 (STGD1), as well as individual patient case reports from the study. Belite's participation wil

    1/29/26 8:00:00 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates

    Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of MRI concordance in imaging study of patients with brain metastases  Interim data from additional Cohorts of the Phase 1 clinical trial of RAD 202 and RAD 204 in advanced solid tumors are expected in mid-2026 Cash and cash equivalents of approximately $34.52 million provide runway into 2027 to advance pipeline of high value radiotherapeutic programs through key clinical and regulatory milestones SYDNEY, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on

    1/28/26 7:00:00 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)

    Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary endpoint in the pivotal, global Phase 3 DRAGON trial with 36% reduction in lesion growth (p-value=0.0033)60 adolescent STGD1 subjects enrolled in DRAGON II clinical trial across Japan, the United States, and the United KingdomBelite Bio plans to file a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in 1H 2026 SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases th

    1/27/26 8:00:00 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    $COE
    $HCM
    $LOT
    SEC Filings

    View All

    SEC Form S-8 filed by Belite Bio Inc

    S-8 - BELITE BIO, INC (0001889109) (Filer)

    1/30/26 8:00:34 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Radiopharm Theranostics Limited

    6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

    1/28/26 7:03:37 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Belite Bio Inc

    6-K - BELITE BIO, INC (0001889109) (Filer)

    1/27/26 8:00:17 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    $COE
    $HCM
    $LOT
    Leadership Updates

    Live Leadership Updates

    View All

    Viomi Technology Co., Ltd Appoints Malaysian Pop Star Shila Amzah as Brand Ambassador and Announces New AI Water Purifier Launch in Malaysia

    GUANGZHOU, China, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Viomi Technology Co., Ltd ("Viomi" or the "Company") (NASDAQ:VIOT), a leading technology company for home water solutions in China, today announced the appointment of renowned Malaysian singer Ms. Shila Amzah as its brand ambassador in Malaysia. Ms. Amzah will join Viomi for a product launch event in Malaysia on October 30, where the Company will unveil its new AI water purifier, INNO, designed to bring a smarter and safer drinking water lifestyle to local households. Mr. Xiaoping Chen, Founder and CEO of Viomi, commented: "We are thrilled to welcome Ms. Shila Amzah as our brand ambassador in Malaysia. Together, at our upcoming product

    10/20/25 9:00:28 AM ET
    $VIOT
    Consumer Electronics/Appliances
    Consumer Discretionary

    HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Professor Tan Shao Weng, Daniel (Chen Shaowen) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from October 15, 2025. Professor Tan, aged 47, has over 20 years of experience in oncology, with his main research interests focusing on thoracic, head and neck malignancies, and drug development. He is the head of the Division of Clinical Trials and Epidemiological Sciences and a senior consultant in the Division of Medical Oncology at the N

    10/14/25 4:30:00 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HUTCHMED Announces Appointment of Acting Chief Executive Officer

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J, Aug. 25, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) today announces that Dr Weiguo Su, an Executive Director of the Company, will take a leave of absence from his duties as Chief Executive Officer due to health reasons. In light of this, the Board of Directors has appointed Mr Johnny Cheng, an Executive Director and Chief Financial Officer of the Company, as Acting Chief Executive Officer with immediate effect, in addition to his role as Chief Financial Officer. Dr Dan Eldar, Chairman and Non-executive Director, said, "The Board expresses its full support for Dr Su and wishes him a speedy recover

    8/24/25 8:20:00 PM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    $COE
    $HCM
    $LOT
    Financials

    Live finance-specific insights

    View All

    51Talk Online Education Group Announces Third Quarter 2025 Results

    SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- 51Talk Online Education Group ("51Talk" or the "Company") (NYSE American: COE), a global online education platform with core expertise in English education, announced its unaudited results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial and Operating Highlights Gross billings[1] for the third quarter of 2025 were US$40.5 million, a 104.6% growth from US$19.8 for the third quarter of 2024.Net revenues for the third quarter of 2025 were US$26.3 million, an 87.5% increase from US$14.0 million for the third quarter of 2024.The number of quarterly active students with attended lesson consumption for the third quarter of 2025 wa

    12/8/25 6:30:00 AM ET
    $COE
    Other Consumer Services
    Real Estate

    51Talk Online Education Group to Report Third Quarter 2025 Financial Results on Monday, December 8, 2025

    Earnings Call Scheduled for 8:00 a.m. ET on December 8, 2025 SINGAPORE, Dec. 3, 2025 /PRNewswire/ -- 51Talk Online Education Group ("51Talk", or the "Company") (NYSE:COE), a global online education platform with core expertise in English education, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2025 on Monday, December 8, 2025, before the open of U.S. markets. The Company's management will host an earnings conference call at 8:00 a.m. U.S. Eastern Time on December 8, 2025 (9:00 p.m. Singapore/Beijing/Hong Kong time on December 8, 2025). Dial-in details for the earnings conference call are as follows: United States Toll: 1-888-34

    12/3/25 4:01:00 PM ET
    $COE
    Other Consumer Services
    Real Estate

    New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease

    Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in a global Phase 3 trial for Stargardt disease, achieving a statistically significant p-value of 0.0033Tinlarebant met the primary efficacy endpoint, demonstrating clinical benefit by significantly reducing the lesion growth rate by 36% compared to placebo, as measured by retinal imagingTinlarebant was well tolerated throughout the trial Stargardt disease impacts more than 50,000 patients in the U.S. Belite Bio plans to file an NDA with the US FDA in 1H 2026Company will host a conference call and webcast today at 8:00 a.m. ET SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite

    12/1/25 6:00:00 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    $COE
    $HCM
    $LOT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by 51Talk Online Education Group

    SC 13D/A - 51Talk Online Education Group (0001659494) (Subject)

    12/17/24 4:07:04 PM ET
    $COE
    Other Consumer Services
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Viomi Technology Co. Ltd

    SC 13G/A - Viomi Technology Co., Ltd (0001742770) (Subject)

    11/12/24 6:35:53 AM ET
    $VIOT
    Consumer Electronics/Appliances
    Consumer Discretionary

    SEC Form SC 13G filed by Lotus Technology Inc.

    SC 13G - Lotus Technology Inc. (0001962746) (Subject)

    11/12/24 6:07:58 AM ET
    $LOT
    Auto Manufacturing
    Industrials